Biotech IPOs Charge Ahead as Tech Deals Stall
TRex Bio and Retension Pharmaceuticals are set to continue the industry’s public debut rebound.
Connecting Global Economies
TRex Bio and Retension Pharmaceuticals are set to continue the industry’s public debut rebound.